Natreon wins patent for tannoid blend extract

US-based Natreon has gained a patent for Terminalia chebula to help pain and inflammation related to osteoarthritis

Natreon, a nutritional ingredient company, has been granted a US patent for Terminalia chebula. This newly granted patent expands Natreon’s patent portfolio to a total of 24 active patents, as well as 40 published clinical trials.

The primary claim in this patent is “a method of treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolysable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract.”

The secondary claim is “a method of reducing pain and inflammation in an individual with osteoarthritis in need thereof, comprising orally administering to the individual in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolysable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract.”

The published randomised, double-blind, placebo-controlled clinical study tested 100 subjects with joint discomfort. Based on the information from which this patent has been issued, the results have shown a significant reduction in WOMAC, KSI, and VAS scores for pain and stiffness.

“Natreon is centered on the idea of ‘trusted science, naturally’ and our investment in clinical research demonstrates our commitment to this ideal. We are excited by the opportunities ahead as the market continues to seek botanical products backed by science,” said Bruce Brown, President of Natreon.

Companies